Hirotaka Kazama

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Systematic Review

Diffuse Large B Cell Lymphoma

Cross Sectional

Top Venues

Japanese journal of clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Hirotaka Kazama, Satoshi Nishina, Takeshi Seto
Safety and effectiveness of clofarabine in Japanese patients with relapsed/refractory acute lymphoblastic leukaemia: a post-marketing surveillance study. Japanese journal of clinical oncology 54 (7) (2024)
Hirotaka Kazama, Satoshi Nishina, Takeshi Seto
Safety and effectiveness of clofarabine in Japanese patients with relapsed/refractory acute lymphoblastic leukaemia: a post-marketing surveillance study. Japanese journal of clinical oncology (2024)
Hirotaka Kazama, Satoshi Nishina, Takeshi Seto
Safety and effectiveness of clofarabine in Japanese patients with relapsed/refractory acute lymphoblastic leukaemia: a post-marketing surveillance study. Japanese journal of clinical oncology 54 (7) (2024)
Hirotaka Kazama, Satoshi Nishina, Takeshi Seto
Safety and effectiveness of clofarabine in Japanese patients with relapsed/refractory acute lymphoblastic leukaemia: a post-marketing surveillance study. Japanese journal of clinical oncology 54 (7) (2024)
Nobuaki Matsubara, Hideyasu Matsuyama, Hirotaka Kazama, Takeshi Seto, Yoshinori Sunaga, Kazuhiro Suzuki
Baseline characteristics may impact treatment duration of cabazitaxel in patients with mCRPC: a subanalysis of data from a post-marketing surveillance. Japanese journal of clinical oncology (2023)